Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment
10.3779/j.issn.1009-3419.2013.10.03
- VernacularTitle:45例晚期非小细胞肺癌EGFR-TKIs治疗获益后出现孤立进展后联合局部治疗的回顾性分析
- Author:
ZHANG XIN
1
;
WANG BIN
;
LIN LIN
;
HAO XUEZHI
;
CHEN SHANSHAN
;
LI JUNLING
;
ZHANG XIANGRU
;
SHI YUANKAI
Author Information
1. 100021北京，中国医学科学院北京协和医学院肿瘤医院内科，抗肿瘤分子靶向药物临床研究北京市重点实验室
- Keywords:
Lung neoplsms;
Epidermal growth factor receptor tyrosine kinase inhibitors;
Solitary progression
- From:
Chinese Journal of Lung Cancer
2013;(10):514-518
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are routine treatments for non-small cell lung cancer (NSCLC) with EGFR mutation. Different clinical modes can be used to treat patients with TKI resistance, one of which is solitary progression. hTe aim of this study is to analyze available treatments for patients undergoing solitary progression. Methods Clinical data of 45 patients with advanced NSCLC who received lo-cal radiotherapy combined with EGFR-TKI atfer solitary progression were reviewed and analyzed. Results Among the 45 patients, 11 showed partial response, 23 achieved stable disease state, and 11 experienced progressive disease. hTe median of progression-free survival (PFS) was 5.9 months. Conclusion Local therapies combined with EGFR-TKIs can prolong the PFS of patients with NSCLC who exhibited solitary progression during EGFR-TKI treatment.
